Brepocitinib yields improvements in cutaneous sarcoidosis | HappeningNow.news

Health · 4 views

Brepocitinib yields improvements in cutaneous sarcoidosis

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the…

Source Summary Published 22m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 4 Community interest
Brief read Under 1 min brief 85 words

Summary

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida. Misha Rosenbach, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined the efficacy and safety of brepocitinib in adults with CS in the Phase II portion of a multicenter, randomized, placebo-controlled trial.

Read original at Medical Xpress

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page